Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Social Justice Institute’s Rhonda Y. Williams comments on collaborative’s suggested changes to consent decree
- The Ralph T. and Esther L. Warburton Foundation makes commitment to CWRU to support scholarships
- Volunteer for 30-day Hough & Glenville Community Health Competition
- Computer, software discounts available for students
- Law’s Jonathan Adler, Jessie Hill discuss Supreme Court rulings on Affordable Care Act subsidies, same-sex marriage